Satellos Bioscience Files 40-F for FY2025

Ticker: MSLE · Form: 40-F · Filed: Mar 27, 2026 · CIK: 0001421642

Sentiment: neutral

Topics: annual-report, foreign-private-issuer

TL;DR

Satellos Bioscience filed its 40-F annual report for 2025. No major news, just routine filing.

AI Summary

Satellos Bioscience Inc. filed its 40-F form on March 27, 2026, reporting on its fiscal year ending December 31, 2025. The filing includes various exhibits such as financial statements and other supplementary information, but does not contain specific financial figures or operational details within the provided text.

Why It Matters

This filing is an annual report for foreign private issuers, providing a summary of their financial and operational status for the fiscal year ending December 31, 2025.

Risk Assessment

Risk Level: low — A 40-F filing is a routine annual report for foreign private issuers and typically does not contain new material information.

Key Players & Entities

FAQ

What is the purpose of a 40-F filing?

A 40-F filing is a registration statement or annual report required for certain foreign private issuers under Section 12 or Section 13(a)/15(d) of the Securities Exchange Act.

What period does this 40-F filing cover?

This 40-F filing covers the period of report ending December 31, 2025.

When was this 40-F filing accepted by the SEC?

This 40-F filing was accepted by the SEC on March 27, 2026, at 08:24:22.

What types of documents are included as exhibits in this filing?

The filing includes various exhibits such as EX-97.1, EX-99.1 through EX-99.8, and numerous graphic files, as well as XBRL formatted documents.

Does the provided filing text contain specific financial figures for Satellos Bioscience Inc. for the 2025 fiscal year?

No, the provided text is a list of documents and their sizes, and does not contain specific financial figures or operational details from the 2025 fiscal year.

Filing Stats: 2,489 words · 10 min read · ~8 pages · Grade level 13 · Accepted 2026-03-27 08:24:22

Filing Documents

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES A. Certifications The required disclosure is included in Exhibits 99.5, 99.6, 99.7 and 99.8 of this Annual Report on Form 40-F. B. Disclosure Controls and Procedures The information provided under the heading "Disclosure Controls and Internal Control Over Financial Reporting" contained in the MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein. C. Management's Annual Report on Internal Control over Financial Reporting The information provided under the heading "Disclosure Controls and Internal Control Over Financial Reporting" contained in the MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein. D. Attestation Report of the Registered Public Accounting Firm The Company is an "emerging growth company" as defined in Rule 12b-2 of the U.S. Securities Exchange Act of 1934, as amended (the " Exchange Act "), and accordingly is not required to provide an attestation report of the registered public accounting firm for the year ended December 31, 2025. E. Changes in Internal Control over Financial Reporting The information provided under the heading "Disclosure Controls and Internal Control Over Financial Reporting" contained in the MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein. NOTICES PURSUANT TO REGULATION BTR There were no notices required by Rule 104 of Regulation BTR that the Registrant sent during the year ended December 31, 2025 concerning any equity security subject to a blackout period under Rule 101 of Regulation BTR. 2 IDENTIFICATION OF THE AUDIT COMMITTEE AND AUDIT COMMITTEE FINANCIAL EXPERT The Registrant's Board of Directors (the " Board ") has a separately designated standing Audit Committee established in accordance with the Exchange Act for the purpose of overseeing the accounting and financial reporting processes of the Registrant and audits of the Registrant's ann

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS Certain statements in this Annual Report on Form 40-F are forward-looking statements within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act of 1933, as amended. Please see "CAUTION REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTORS" in the AIF, filed as Exhibit 99.1 to this Annual Report on Form 40-F for a discussion of risks, assumptions, uncertainties and other factors that could cause actual results to vary from those forward-looking statements. 4 UNDERTAKING Registrant undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to: the securities registered pursuant to Form 40-F; the securities in relation to which the obligation to file an annual report on Form 40-F arises; or transactions in said securities. CONSENT TO SERVICE OF PROCESS The Registrant has previously filed a Form F-X, dated February 5, 2026, in connection with its Common Shares, the class of securities in relation to which the obligation to file this Annual Report on Form 40-F arises. Any change to the name or address of the Registrant's agent for service shall be communicated promptly to the Commission by amendment to Form F-X referencing the file number of the Registrant. 5 Exhibit Index Exhibit No. Document 97.1 The Registrant's Clawback Policy. 99.1 Annual Information Form of the Registrant for the fiscal year ended December 31, 2025. 99.2 Audited Consolidated Financial Statements of the Registrant as of and for the years ended December 31, 2025 and 2024. 99.3 Management's Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2025. 99.4 Consent of Independent Registered Public Accounting Firm – PricewaterhouseCoopers LLP 99.5 Certification of Chief Executive Officer (Principal Execut

SIGNATURES

SIGNATURES Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this annual report to be signed on its behalf by the undersigned, thereto duly authorized. Date: March 27, 2026 Satellos Bioscience Inc. By: /s/ Elizabeth Williams, CPA, CA Name: Elizabeth Williams, CPA, CA Title: Chief Financial Officer 7

View Full Filing

View this 40-F filing on SEC EDGAR

View on Read The Filing